Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00313885 |
Fibromyalgics frequently report sleep disturbances, in particular poor and unrefreshing sleep. Additionally, studies have reported that sleep problems, pain and mood disturbances are associated in patients with fibromyalgia. By improving the quality of sleep, complaints of poor and unrefreshing sleep, fatigue, pain, which are among the main components of this chronic pain disorder may be improved.
Condition | Intervention | Phase |
---|---|---|
Fibromyalgia Sleep Chronic Pain |
Drug: eplivanserin (SR46349) Drug: placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study. |
Enrollment: | 205 |
Study Start Date: | April 2004 |
Study Completion Date: | June 2005 |
Primary Completion Date: | June 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
1 mg daily
|
Drug: eplivanserin (SR46349)
oral administration
|
2: Experimental
5 mg daily
|
Drug: eplivanserin (SR46349)
oral administration
|
3: Placebo Comparator |
Drug: placebo
oral administration
|
The purpose of this research study is to investigate the effectiveness and safety of 2 doses of the investigational product in subjects with sleep disorders with fibromyalgia as compared to placebo (a substance which contains no active ingredient). The study will last approximately 70 days and will include 7 office visits.
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Radiant Research | |
Phoenix, Arizona, United States, 85013 | |
United States, California | |
San Diego Arthritis Medical Clinic | |
San Diego, California, United States, 92108 | |
United States, Florida | |
Renstar Medical Research | |
Ocala, Florida, United States, 34471 | |
Miami Research Assoc., Inc. | |
Miami, Florida, United States, 33173 | |
Jacksonville Center for Clinical Research | |
Jacksonville, Florida, United States, 32216 | |
United States, Georgia | |
Comprehensive Neuroscience | |
Atlanta, Georgia, United States, 30328 | |
United States, Indiana | |
Physicians Research Group | |
Indianapolis, Indiana, United States, 46250 | |
United States, Kansas | |
Wichita Clinic PA | |
Wichita, Kansas, United States, 67208 | |
United States, Nebraska | |
Westroads Medical Group | |
Omaha, Nebraska, United States, 68114 | |
United States, Utah | |
Physicians Research Options | |
Ogden, Utah, United States, 84403 | |
United States, Washington | |
Seattle Rheumatology Assoc. | |
Seattle, Washington, United States, 98104 | |
Canada | |
Sanofi-Aventis Administrative Office | |
Laval, Canada |
Study Director: | ICD CSD | Sanofi-Aventis |
Responsible Party: | sanofi-aventis ( ICD Study Director ) |
Study ID Numbers: | ACT5400 |
Study First Received: | April 7, 2006 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00313885 |
Health Authority: | United States: Food and Drug Administration |
Fibromyalgia Myofascial Pain Syndromes Sleep Disorders Pain Rheumatic Diseases Serotonin Signs and Symptoms |
Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Mental Disorders SR 46349B Neurologic Manifestations |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Hematologic Agents Physiological Effects of Drugs Fibrinolytic Agents Cardiovascular Agents |
Pharmacologic Actions Fibrin Modulating Agents Serotonin Antagonists Serotonin Agents Therapeutic Uses Platelet Aggregation Inhibitors |